Aim:

The aim of the study is to evaluate the safety and efficacy of oral semaglutide in improving glycemic control and promoting weight reducton In  patientse with type 2 diabetes and obesity.

Objectives:

Main Objective: 

           To assess the efficacy of oral semaglutide in reducing HbA1c levels in South Indian patients with type 2 diabetes and obesity treated at a tertiary care hospital.

          Secondary Objectives:

1.     To assess the degree of weight reduction achieved with treatment.

2.     To monitor and document any adverse events associated with oral semaglutide use in South Indian patients

3.     Record the incidence and types of adverse effects in this population.

4.     To determine patient adherence and satisfaction with oral semaglutide therapy over the study period..

STUDY DESIGN: Observational Prospective Cohort Study

EXPECTED OUTCOME OF THE STUDY:

The study is expected to demonstrate a significant reduction in HbA1c levels, likely around 1%, showing effective glycemic control in South Indian patients with type 2 diabetes and obesity. Clinically meaningful weight loss (5-10% of body weight) is also anticipated, alongside improvements in fasting blood glucose and cardiovascular risk factors such as blood pressure and lipid profiles.

The safety profile should be favorable, with gastrointestinal side effects like nausea and vomiting being the most common, and a low incidence of serious adverse events like hypoglycemia or pancreatitis. Subgroup analyses may reveal differences in efficacy based on age, gender, or baseline BMI.

The study will likely support oral semaglutide as an effective and safe treatment option, contributing to better management of diabetes and obesity in the South Indian population. These findings could guide clinical protocols in tertiary care hospitals.